{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"12"},{"groupId":"OG009","value":"27"}],"units":"Participants"}],"description":"Non-progression rate (NPR) at 27 weeks was defined as the percentage of efficacy evaluable patients who were alive and progression-free at 27 weeks as assessed by irRECIST\n\nProgression is defined using immune-related Response Evaluation Criteria in Solid Tumors (irRECIST), as an increase ≥ 20% (minimum 5 mm) in total measured tumor burden compared with nadir or progression of non-target lesions or new lesion","groups":[{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG000","title":"Cohort 1: Squamous Cell Carcinoma of the Skin"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG001","title":"Cohort 2: Small Cell Malignancies of Nonpulmonary Origin"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG002","title":"Cohort 3: Adrenocortical Carcinoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG003","title":"Cohort 4: Medullary Renal Cell Carcinoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG004","title":"Cohort 5: Carcinoma of Unknown Primary"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG005","title":"Cohort 6: Penile Carcinoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG006","title":"Cohort 7: Vascular Sarcoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG007","title":"Cohort 8: Germ Cell Tumor"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG008","title":"Cohort 9: Paraganglioma-pheochromocytoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG009","title":"Cohort 10: Other Rare Tumor Histologies"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients who have received at least 1 dose of study medication with at least 1on-study tumor assessment were included in the analysis. If a patient discontinued before the first radiological assessment due to progression, they were included in the analysis. If the patient discontinued before 27 weeks due to reasons other than progression or death, they were considered non evaluable for this endpoint. One patient enrolled in the ACC cohort was excluded due to change in diagnosis.","reportingStatus":"POSTED","timeFrame":"At 27 weeks","title":"Non-progression Rate (NPR) at 27 Weeks by irRECIST","type":"PRIMARY","unitOfMeasure":"Participants"}